Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bone Biologics Corp. (BBLG : NSDQ)

• Company Description    Bone Biologics Corp. is a developer of orthobiologic products for spine fusion markets. Bone Biologics Corp. is based in BURLINGTON, Mass. Number of Employees: 2

• Price / Volume Information    Yesterday's Closing Price: $1.07 Daily Weekly Monthly 20 Day Moving Average: 46,933 shares Shares Outstanding: 1.81 (millions) Market Capitalization: $1.94 (millions) Beta: 0.90 52 Week High: $3.13 52 Week Low: $1.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.15% -20.74% 12 Week -17.05% -19.33% Year To Date -26.21% -31.18%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 BURLINGTON WOODS DRIVE SUITE 100 - BURLINGTON,MA 01803 USA ph: 781-552-4452 fax: - investors@bonebiologics.com http://www.bonebiologics.com

• General Corporate Information    Officers Jeffrey Frelick - Chief Executive Officer Deina H. Walsh - Chief Financial Officer Bruce Stroever - Director Robert Gagnon - Director Phillip Meikle - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 098070600 SIC: 3842 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 1.81 Most Recent Split Date: 6.00 (0.17:1) Beta: 0.90 Market Capitalization: $1.94 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.18 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.17 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.41 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 77.60% vs. Previous Quarter: -207.14% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -50.47 12/31/25 - -59.52 ROA 06/30/26 - - 03/31/26 - -47.40 12/31/25 - -55.76 Current Ratio 06/30/26 - - 03/31/26 - 16.11 12/31/25 - 13.83 Quick Ratio 06/30/26 - - 03/31/26 - 16.11 12/31/25 - 13.83 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - 2.60 12/31/25 - 3.00 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©